company background image
HSTO

Histogen NasdaqCM:HSTO Stock Report

Last Price

US$2.33

Market Cap

US$5.8m

7D

-1.7%

1Y

-89.3%

Updated

29 Jun, 2022

Data

Company Financials +
HSTO fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

HSTO Stock Overview

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products.

Histogen Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Histogen
Historical stock prices
Current Share PriceUS$2.33
52 Week HighUS$22.20
52 Week LowUS$2.06
Beta-0.17
1 Month Change-33.96%
3 Month Change-53.40%
1 Year Change-89.31%
3 Year Changen/a
5 Year Changen/a
Change since IPO-97.47%

Recent News & Updates

Shareholder Returns

HSTOUS BiotechsUS Market
7D-1.7%3.8%1.6%
1Y-89.3%-25.8%-20.8%

Return vs Industry: HSTO underperformed the US Biotechs industry which returned -26.1% over the past year.

Return vs Market: HSTO underperformed the US Market which returned -20.4% over the past year.

Price Volatility

Is HSTO's price volatile compared to industry and market?
HSTO volatility
HSTO Average Weekly Movement25.7%
Biotechs Industry Average Movement13.1%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: HSTO is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 26% a week.

Volatility Over Time: HSTO's weekly volatility has increased from 14% to 26% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200722Steve Mentohttps://www.histogen.com

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company’s preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease.

Histogen Fundamentals Summary

How do Histogen's earnings and revenue compare to its market cap?
HSTO fundamental statistics
Market CapUS$5.82m
Earnings (TTM)-US$11.35m
Revenue (TTM)US$4.36m

1.3x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HSTO income statement (TTM)
RevenueUS$4.36m
Cost of RevenueUS$8.25m
Gross Profit-US$3.90m
Other ExpensesUS$7.46m
Earnings-US$11.35m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-4.55
Gross Margin-89.44%
Net Profit Margin-260.63%
Debt/Equity Ratio0%

How did HSTO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is HSTO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HSTO?

Other financial metrics that can be useful for relative valuation.

HSTO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does HSTO's PS Ratio compare to its peers?

HSTO PS Ratio vs Peers
The above table shows the PS ratio for HSTO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average24.5x
ANPC AnPac Bio-Medical Science
4.4xn/aUS$11.8m
CELZ Creative Medical Technology Holdings
64.3x90.7%US$6.6m
HCYT.D H-CYTE
3.2xn/aUS$5.1m
ADTX Aditxt
28.4xn/aUS$8.9m
HSTO Histogen
1.3x54.0%US$5.8m

Price-To-Sales vs Peers: HSTO is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (24.5x).


Price to Earnings Ratio vs Industry

How does HSTO's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: HSTO is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Biotechs industry average (13.4x)


Price to Sales Ratio vs Fair Ratio

What is HSTO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HSTO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio1.9x

Price-To-Sales vs Fair Ratio: HSTO is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).


Share Price vs Fair Value

What is the Fair Price of HSTO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HSTO ($2.33) is trading below our estimate of fair value ($750.68)

Significantly Below Fair Value: HSTO is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HSTO's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Histogen forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


54.0%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if HSTO's forecast earnings growth is above the savings rate (1.9%).

Earnings vs Market: Insufficient data to determine if HSTO's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if HSTO's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HSTO's revenue (54% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: HSTO's revenue (54% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HSTO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Histogen performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-37.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: HSTO is currently unprofitable.

Growing Profit Margin: HSTO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HSTO is unprofitable, and losses have increased over the past 5 years at a rate of 37.8% per year.

Accelerating Growth: Unable to compare HSTO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HSTO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: HSTO has a negative Return on Equity (-47.65%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Histogen's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: HSTO's short term assets ($25.8M) exceed its short term liabilities ($2.9M).

Long Term Liabilities: HSTO's short term assets ($25.8M) exceed its long term liabilities ($4.7M).


Debt to Equity History and Analysis

Debt Level: HSTO is debt free.

Reducing Debt: HSTO had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HSTO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HSTO has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 48.5% each year.


Discover healthy companies

Dividend

What is Histogen current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate HSTO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HSTO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HSTO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HSTO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HSTO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

Steve Mento (69 yo)

0.58

Tenure

US$686,206

Compensation

Dr. Steven J. Mento, also known as Steve, Ph D., has been an Executive Chairman, Interim President and Chief Executive Officer of Histogen Inc. since November 08, 2021. Dr. Mento has been an Independent Di...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD686.21K) is about average for companies of similar size in the US market ($USD759.63K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: HSTO's management team is seasoned and experienced (5.1 years average tenure).


Board Members

Experienced Board: HSTO's board of directors are considered experienced (8.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.7%.


Top Shareholders

Company Information

Histogen Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Histogen Inc.
  • Ticker: HSTO
  • Exchange: NasdaqCM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$5.819m
  • Shares outstanding: 2.50m
  • Website: https://www.histogen.com

Number of Employees


Location

  • Histogen Inc.
  • 10655 Sorrento Valley Road
  • Suite 200
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/29 00:00
End of Day Share Price2022/06/29 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.